Clinical Trials Logo

Filter by:
NCT ID: NCT01087723 Completed - Clinical trials for Acute Coronary Syndrome

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

EUROMAX
Start date: March 2010
Phase: Phase 3
Study type: Interventional

To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary percutaneous coronary intervention (PCI) management strategy, presenting either via ambulance or to centers where PCI is not performed.

NCT ID: NCT01087151 Completed - Clinical trials for Chronic Lymphocytic Leukemia

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This Phase II, randomized, open-label, international, multicenter trial is designed to evaluate the safety and efficacy of rituximab monotherapy when given according to a dose intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when combined with dose-intense rituximab in previously untreated patients with B-cell CLL.

NCT ID: NCT01086761 Terminated - Clinical trials for Wet Age-Related Macular Degeneration

Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.

NCT ID: NCT01085487 Completed - Clinical trials for Idiopathic Menorrhagia

MiCo - Mirena or Conventional Medical Treatment for Menorrhagia

Start date: April 2009
Phase: N/A
Study type: Observational

The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of heavy menstrual bleeding (Menorrhagia) under daily-life treatment conditions.For each patient, an initial visit and one to three follow-up visits after about 3, 6 and 12 months will be documented by the treating physician on the case report form. Observations include the patient's demographic parameters (date of birth, height, weight, race and smoking habits), previous contraceptives and menorrhagia treatment, gynaecological history, baseline menstruation, result of insertion, concomitant medications and diseases as well as menorrhagia symptoms. Overall treatment success will be evaluated at the end of treatment including number of weeks until improvement and reduction of menstrual bleeding with respect to duration and severity, and patient's satisfaction.

NCT ID: NCT01081925 Recruiting - Clinical trials for Congestive Heart Failure

Congestive Heart Failure: Causes of Sudden Worsening

Start date: February 2010
Phase: N/A
Study type: Observational

The purpose of the study is to recognize main causes of acute decompensation of chronic congestive heart failure.

NCT ID: NCT01081782 Completed - Multiple Sclerosis Clinical Trials

A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis

DreaMS
Start date: March 2010
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of ONO-4641 in patients with relapsing-remitting multiple sclerosis over a 26-week treatment period.

NCT ID: NCT01081769 Completed - Schizophrenia Clinical Trials

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

PROSIPAL
Start date: February 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy (how well the drug works; primarily through the time to relapse) of long-acting injectable paliperidone palmitate compared to treatment as usual with orally administered antipsychotics in monotherapy over 24 months in the treatment of recently diagnosed (1-5 years since diagnosis) schizophrenia.

NCT ID: NCT01080209 Completed - Clinical trials for Patients Who Participated in an Intravitreal Brimo PS DDS® Study

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

Start date: February 2010
Phase: Phase 2
Study type: Interventional

This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.

NCT ID: NCT01079195 Completed - Hypertension Clinical Trials

Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus

TARDIA
Start date: October 2007
Phase: N/A
Study type: Observational

The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a community setting and in accordance with the terms of the local marketing authorization. The following specific questions will be addressed: - Effectiveness of Tarka in lowering the blood pressure in hypertensive patients being at high risk of developing diabetes, not controlled on single-drug therapy. - Tolerability of Tarka as assessed by withdrawal rates.

NCT ID: NCT01078623 Completed - Clinical trials for Chronic Obstructive Pulmonary Disease

Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate

ALIGHT-COPD
Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in patients with stable, moderate to severe COPD. Every treatment period is 14-days long and there is a 7-days wash-out period in between them. The trial starts with a run in phase of 10 to 17-days duration and it ends up with a follow up contact 14-days after last treatment dose.